Influence of Treatment with Ultralow-dose Aspirin on Platelet Aggregation As Measured by Whole Blood Impedance Aggregometry and Platelet P-selectin Expression in Clinically Normal Dogs
Overview
Authors
Affiliations
Objective: To evaluate the influence of treatment with ultralow-dose aspirin (ULDAsp) on platelet aggregation, P-selectin (CD62P) expression, and formation of platelet-leukocyte aggregates in clinically normal dogs.
Animals: 18 clinically normal dogs.
Procedures: Studies were conducted before and 24 hours after ULDAsp administration (0.5 mg/kg, PO, q 24 h, for 2 days). Whole blood impedance aggregometry for the assessment of platelet function was performed with sodium citrate-anticoagulated blood and aggregation agonists (ADP at 20, 10, and 5 μmol/L; collagen at 10, 5, and 2 μg/mL). Onset, maximum response, and rate of platelet aggregation were recorded. Flow cytometric assays were configured to detect thrombin-induced CD62P expression and platelet-leukocyte aggregates in EDTA-anticoagulated whole blood. Externalized platelet CD62P and constitutive CD61 (GPIIIa) were labeled with antibodies conjugated to phycoerythrin (PE) and fluorescein isothiocyanate (FITC), respectively. Red blood cell-lysed paraformaldehyde-fixed EDTA-anticoagulated whole blood was dual labeled with CD61-FITC and a panleukocyte antibody (CD18-PE) to characterize platelet-leukocyte aggregates.
Results: ULDAsp significantly delayed platelet aggregation onset with ADP at 20 μmol/L by 54% to 104%, attenuated maximum aggregation with various concentrations of ADP and collagen by ≥ 41%, and slowed aggregation rate with the highest ADP and collagen concentrations by ≥ 39%. Depending on the parameter tested, up to 30% of dogs failed to have an ULDAsp effect. Thrombin stimulation significantly increased CD62P expression in platelets and platelet-leukocyte aggregates, but ULDAsp did not alter basal or thrombin-stimulated CD62P expression.
Conclusions And Clinical Relevance: ULDAsp treatment of clinically normal dogs impaired platelet aggregation in most dogs, but did not influence CD62P platelet membrane expression.
Platelet number and function in response to a single intravenous dose of vincristine.
Allen E, Tarigo J, LeVine D, Barber J, Brainard B J Vet Intern Med. 2021; 35(4):1754-1762.
PMID: 33993531 PMC: 8295686. DOI: 10.1111/jvim.16169.
Shropshire S, Johnson T, Olver C J Vet Intern Med. 2020; 34(2):710-718.
PMID: 31981378 PMC: 7096639. DOI: 10.1111/jvim.15694.
Proteomic profiling of the thrombin-activated canine platelet secretome (CAPS).
Cremer S, Catalfamo J, Goggs R, Seemann S, Kristensen A, Brooks M PLoS One. 2019; 14(11):e0224891.
PMID: 31721811 PMC: 6853320. DOI: 10.1371/journal.pone.0224891.
ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.
Swann J, Garden O, Fellman C, Glanemann B, Goggs R, LeVine D J Vet Intern Med. 2019; 33(3):1141-1172.
PMID: 30847984 PMC: 6524099. DOI: 10.1111/jvim.15463.